# Novel Oral HAE Drug Measures Up to Injectable Options

Source: [MedPageToday.com - medical news for physicians](https://www.medpagetoday.com/meetingcoverage/acaai/123983) · 2026-11-20 · Medicine
Page: https://themorning.science/story/novel-oral-hae-drug-measures-up-to-injectable-options-5d23d75627f84aa8
Kind: research · Impact: medium

## In brief

- A pivotal phase III trial found that prophylactic use of oral deucrictibant, a bradykinin B2 receptor antagonist, substantially reduced hereditary angioedema attacks.
- The primary endpoint was assessed for an extended-release formulation of deucrictibant.
- The results were reported by MedPage Today from ACAAI meeting coverage, which compares the oral drug with injectable options.

## Why it matters

If confirmed, an oral prophylactic option could offer an alternative to injectable treatments for people with hereditary angioedema.

## Coverage

- [Novel Oral HAE Drug Measures Up to Injectable Options](https://www.medpagetoday.com/meetingcoverage/acaai/123983) — MedPageToday.com - medical news for physicians, 2026-11-20

Tags: hereditary angioedema, deucrictibant, clinical trial, drug development, immunology

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science
